With the engineered attenuated Salmonella typhimurium VNP20009 expressing mutated IL-2 or sPD-1 driven by SORT, US could spatiotemporally trigger production and secretion of IL-2 or sPD-1 in various syngeneic tumor mouse models, thereby achieving robust therapeutic efficacy while minimizing toxic effects. The gene discussed is IL2; the disease is neoplasm.